Tuesday, November 5, 2024

Gestalt and Paige Partner to Enhance Digital Pathology Workflows

Related stories

Absci and Twist Bioscience Collaborate to Design Novel Antibody using Generative AI

Absci Corporation a data-first generative AI drug creation company, and...

GreyNoise Intelligence Discovers Zero-Day Vulnerabilities in Live Streaming Cameras with the Help of AI

GreyNoise Intelligence, the cybersecurity company providing real-time, verifiable threat...

Medidata Launches Bundled Solutions to Support Oncology and Vaccine Trials

Medidata, a Dassault Systèmes brand and leading provider of...

Blend Appoints Mike Mischel as SVP of AI Consulting

Blend, a leader in data science and AI-powered solutions,...

Patronus AI Launches Industry-First Self-Serve API for AI Evaluation and Guardrails

Patronus AI announced the launch of the Patronus API, the first...
spot_imgspot_img

Gestalt, a leader in digital pathology solutions, and Paige, the leader in next-generation AI technology for pathology, are excited to announce a strategic partnership to integrate Paige’s advanced AI applications within Gestalt’s award-winning PathFlow solution. This collaboration aims to streamline the delivery of integrated workflows, optimizing the pathologist’s experience while ensuring patient accuracy and safety by working in a single environment.

Gestalt’s PathFlow is widely recognized for its robust capabilities in primary diagnosis, education, resident training, and research workflows. By incorporating Paige’s cutting-edge algorithms, the PathFlow solution will now offer an even broader range of tools to support pathologists in delivering precise and efficient diagnoses.

All of Paige’s AI applications will be made available in PathFlow, enabling both current and new users to seamlessly access AI-powered diagnostic capabilities. This integration supports more efficient case reviews, accelerates diagnostic timelines, and promotes a comprehensive approach to cancer detection.

Also Read: Bioptimus and Proscia Join Forces to Enhance AI in Drug Development

Key Highlights of the Partnership:

  • Enhanced Diagnostic Confidence: The integration of Paige’s AI applications will provide pathologists with powerful tools to improve diagnostic confidence and patient outcomes.
  • Streamlined Workflows: The combined technologies will ensure seamless workflows, reducing the time and effort required for pathologists to reach diagnoses.
  • Comprehensive Support: PathFlow’s expanded algorithm library will cater to a wide range of use cases, benefiting both current and future customers.
  • Paige’s availability through PathFlow’s platform will allow easy access to Paige AI solutions for any Gestalt user.

“By partnering with Paige to include their AI applications in PathFlow, we are reinforcing our commitment to providing pathologists with the best tools available,” said Lisa-Jean Clifford, COO & Chief Strategy Officer of Gestalt. “This partnership underscores our dedication to enhancing the pathologist’s experience and ensuring the highest standards of patient care.”

“Leveraging Paige’s AI-powered applications, PathFlow users can experience an enhanced workflow that supports efficient case review, accelerates time to diagnosis, and allows for a more comprehensive approach to cancer detection, enabling pathologists to focus on what matters most—delivering precise and actionable insights for patient care,” said Peter Hamilton, General Manager for Diagnostics at Paige.

SOURCE: PRNewswire

Subscribe

- Never miss a story with notifications


    Latest stories

    spot_img